0001750284-18-000001.txt : 20180827 0001750284-18-000001.hdr.sgml : 20180827 20180827130157 ACCESSION NUMBER: 0001750284-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180827 DATE AS OF CHANGE: 20180827 EFFECTIVENESS DATE: 20180827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-320082 FILM NUMBER: 181038566 BUSINESS ADDRESS: STREET 1: 665 3RD STREET SUITE 250 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: 4157428265 MAIL ADDRESS: STREET 1: 665 3RD STREET SUITE 250 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 D 1 primary_doc.xml X0708 D LIVE 0001750284 Olema Pharmaceuticals, Inc. 665 3RD STREET SUITE 250 SAN FRANCISCO CA CALIFORNIA 94107 4157428265 DELAWARE CombiThera, Inc. None Corporation true Cyrus Harmon 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Director Peter Kusher 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Director Andrew Rappaport 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Gorjan Hrustanovic 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Andrei Manoliu 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Marina Bozilenko 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Frank McCormick 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director Lawrence Fritz 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Director David Myles 665 3rd Street, Suite 250 San Francisco CA CALIFORNIA 94107 Executive Officer Pharmaceuticals $5,000,001 - $25,000,000 06b false 2018-07-19 false true true Series A-1 Preferred stock, Series A Preferred Stock, and Common Stock Issuable upon conversion thereof; Common Stock issued upon conversion of promissory notes. false 0 6054922 6054922 0 false 13 0 0 0 false Olema Pharmaceuticals, Inc. /s/ Cyrus L. Harman Cyrus L. Harman CEO 2018-08-23